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Purpose.T oe v a l u a t ee ﬀects of corneal transplantation on the health-related quality of life and patients’ satisfaction. Methods.
Patients scheduled for elective penetrating or anterior lamellar keratoplasty completed by telephone interview the SF-12 Health
Survey, before and one year after surgery, and a 6-item questionnaire on the satisfaction for graft outcomes. Results. The two
questionnaires were answered by 1,223 patients. Transplantation did not inﬂuence the PCS-12 in males (ES =− 0.01) and had a
negative eﬀect in females (ES =− 0.18). Both sexes improved their MCS-12 (ES = 0.18 and 0.23, resp.). The majority of patients
(83.1%) were satisﬁed by the outcome of the graft. Conclusions. This is the ﬁrst report on the use of the SF-12 and one of the
few that assess quality of life in patients after corneal transplantation. We showed that grafting improves patients’ health-related
quality of life results of patients, inﬂuencing mental health (i.e., psychological attitude, social interaction, and emotions) with
minor eﬀects on physical health (limitation, pain, and vitality).
1.Introduction
Health-related quality of life (HRQOL) refers to issues as-
sociated with a person’s perception of physical and mental
well-being, which can be aﬀected by illness and medical
treatment [1]. The use of standardized instruments increases
the capability to convert patients’ subjective opinions, rat-
ings, and reports concerning their health, in an informative
way, which can be used to assess the overall health status and
tomonitorchangesinHRQOL[2].Moreover,theassessment
of patient’s HRQOL plays an increasingly important role
in the evaluation of primary or secondary outcomes of
treatments, as documented in a number of clinical studies
[3].
Measuringqualityoflifeinophthalmologyhasbeencon-
ﬁrmed as an important tool for evaluating eye diseases and
the impact of interventions [4–6].
Some corneal diseases, usually in the late stage, require
corneal transplantation [7] ,w h i c hi sm o s t l yp e r f o r m e do n
an elective basis. Criteria for success primarily depend on the
indication for surgery, that is, improvement of visual acuity,
pain relief, and maintenance of the structural integrity of
the eye [8]. The clinical outcome is normally graded by the
caregiver and might not completely reveal the overall bene-
ﬁts, or detriments, perceived by the patient [9].
Actually, patients can easily appraise the graft and esti-
mate the overall results on daily living and in respect of their
expectations. Furthermore, while corneal transplantation is2 Journal of Ophthalmology
performed to treat a corneal disease, surgeons have a rea-
sonable expectation that surgery will lead to a signiﬁcant im-
provement in their patient’s overall physical and mental
health [10].
However, the global impact of the corneal transplanta-
tiononthepatient’shealthstatusorsatisfactionislargelyun-
known.
Studies that have considered the issue of health status
in corneal transplantation have used vision-targeted health-
related quality of life instruments (VF-14, VFQ) [11, 12]
or generic health status questionnaires (e.g., SF-36 Health
Survey) [13], within longitudinal [14–16] or cross-sectional
studies [17, 18].
Despite the disparities in the number of patients, such
studies have shown that postgraft visual function signiﬁ-
cantly aﬀects health status and that visual acuity in the non-
operated eye is the strongest factor associated with improve-
ment of visual function.
Only two published surveys [19, 20] deal with patients’
satisfaction after corneal transplantation, and they point out
that patients’ education and pregraft expectations aﬀect the
perception of success more than the actual clinical outcome.
In the framework of the Corneal Transplant Epidemi-
ological Study (CORTES) [21, 22], that was performed to
understand corneal transplantation in Italy, and to examine
the long-term graft survival, we assessed the eﬀect of such
surgery on patients’ HRQOL and satisfaction. Moreover, the
HRQOLresultswerecomparedwiththoseofarepresentative
sample of healthy subjects of the Italian population.
2.MaterialsandMethods
2.1.Patients. ThecorneasdistributedbytheVenetoEyeBank
Foundation (about 2,000 per year in the 2002–2008 period)
represent approximately 40% of corneal tissues transplanted
in Italy [23].
All the consecutive patients scheduled for elective pene-
trating or anterior lamellar keratoplasty during the CORTES
recruitment period (October 2001–October 2004) were
considered eligible for HRQOL and satisfaction evaluation.
Exclusion criteria were age below 18 years, presence of
invalidating diseases that could cause diﬃculties during the
interview, and patient or surgeon refusal of the interview.
HRQOL data were collected through standardized tele-
phone interviews, carried out by personnel of the CORTES
Follow-Up Unit during the week prior to corneal transplan-
tation and one year following surgery. Assessment of patient
satisfaction was completed at the time of the second inter-
view.
Patients’ clinical history, type of intervention, postopera-
tive clinical assessment, adverse reactions and complications,
and visual acuity and graft condition after one year were
obtained from the CORTES database.
ThestudyprotocolwasapprovedbytheEthicalCommit-
tee of the University of Padua. Full details about the study
and the list of contributing surgeons have been reported
elsewhere [21].
2.2. The SF-12 Health Survey. The SF-12 Health Survey [24]
is a multipurpose, generic 12-item questionnaire developed
from the Short Form-36 (SF-36) that is one of the most
widely used health status evaluation tools. The SF-12 pro-
vides a shorter but still valid and reliable alternative to the
SF-36 for use in large samples.
The questionnaire, validated in Italian [3, 25]a n du s e d
previously in ophthalmic research [26], estimates scores for
eight health concepts: physical functioning, role limitations
due to physical health problems, role limitations due to emo-
tional health problems, mental health (scored using two
items each) bodily pain, general health, vitality, and social
functioning(estimatedusingoneitemeach).SF-12produces
two synthetic measures evaluating physical (limitation, pain,
and vitality) and mental (psychological attitude, social
interaction, and emotions) aspects of health, the Physical
ComponentSummary(PCS-12)andtheMentalComponent
Summary (MCS-12). These measures correlate with the SF-
36 in the 0.94–0.97 range [25].
Validation studies showed that PCS-12 and MCS-12
rangefr om11t o70andfr om7t o72,r especti v ely .Bothsum-
mary scores are standardized to have a mean of 50 and a
standard deviation of 10, with higher scores indicating better
health status perception [27].
SF-12 summary scores were examined in relation to soci-
odemographic and graft-related variables. On the basis of
previous results [27] it was expected that females, elderly
people,widows,divorcedpeople,andthosewhohavealower
education or are unemployed would report poorer health
status.
2.3. Patient Satisfaction Assessment. To evaluate satisfaction
we used 6 items on expectation and satisfaction comprised
in the 24-item questionnaire designed by Williams et al. at
Flinders University of South Australia, Adelaide [19]. Sat-
isfaction questionnaires were administered to patients one
year after surgery following the SF-12 interview.
2.4. Statistical Analysis. Patients who completed the two SF-
12 interviews and the satisfaction questionnaire were con-
sidered for evaluation.
Analyses on the SF-12 were conducted with SAS version
9.1.3 statistical software (SAS Institute Inc., Cary, NC, USA)
following the methods reported in the user manual [27].
Mean values and 95% conﬁdence intervals for PCS-12
and MCS-12 were calculated according to patients’ social
and disease-related characteristics reported to inﬂuence the
HRQOL.
Results of descriptive analyses are expressed as mean and
standard deviation (SD) for quantitative variables and as
counts and percentages for categorical variables, unless oth-
erwise speciﬁed. Chi square test was used to compare cate-
gorical variables in eligible and interviewed patients and
Wilcoxon-Mann-Whitney nonparametric test to compare
median of ages. Chi square test was also used to evaluate dif-
ferences among patients in relation to their satisfaction after
transplantation. All P values are two tailed.Journal of Ophthalmology 3
Table 1: Sociodemographic and clinical characteristics of patients.
Cohort No. (%) Eligible No. (%) Interviewed No. (%)∗
P value
†
5,210 (100) 2,329 (44.7) 1,223 (52.5)
Gender 0.858
Male 3,040 (58.3) 1,362 (58.5) 719 (58.8)
Female 2,170 (41.7) 967 (41.5) 504 (41.2)
Age (y)
Mean (SD) 49.0 (19.8) 46.8 (17.9) 45.8 (16.9)
Male 46.0 (19.2) 44.1 (17.6) 43.9 (16.8)
Female 53.1 (19.9) 50.4 (17.8) 48.6 (16.6)
Median 46.0 44.0 43.0 0.266
Male 42.0 40.0 41.0 0.972
Female 53.0 49.0 47.0 0.084
Marital status
Married
n.c. n.c.
676 (57.1)
Single 412 (34.8)
Widow 62 (5.2)
Divorced 34 (2.9)
Unreported 39
Education
High school
n.c. n.c.
457 (39.4)
Secondary school 311 (26.8)
Primary school 227 (19.6)
Degree 143 (12.3)
None 22 (1.9)
Unreported 63
Working status
Partial or full time
n.c. n.c.
632 (55.6)
Retired 222 (19.5)
House keeper 181 (15.9)
Student 65 (5.7)
Jobless 36 (3.2)
Unreported 87
Reason for graft 0.026
Optical 4,183 (90.8) 1,994 (92.5) 1,085 (94.7)
Tectonic 228 (4.9) 84 (3.9) 26 (2.3)
Pain reduction 197 (4.3) 78 (3.6) 34 (3.0)
Unreported 602 173 78
Type of keratoplasty 0.227
Penetrating 4,696 (90.1) 2,157 (92.6) 1,146 (93.7)
Anterior lamellar 514 (9.9) 172 (7.4) 77 (6.3)
Clinical indication 0.386
Ectasia/thinning 2,550 (48.9) 1,298 (55.7) 730 (59.7)
Regraft (related or not to rejection) 674 (12.9) 304 (13.0) 148 (12.1)
Pseudophakic corneal edema 594 (11.4) 195 (8.4) 87 (7.1)
Primary endotheliopathies 335 (6.4) 140 (6.0) 82 (6.7)
Mechanical trauma 174 (3.3) 76 (3.3) 36 (3.0)4 Journal of Ophthalmology
Table 1: Continued.
Cohort No. (%) Eligible No. (%) Interviewed No. (%)∗
P value
†
5,210 (100) 2,329 (44.7) 1,223 (52.5)
Viral/postviral keratitis 129 (2.5) 50 (2.2) 25 (2.0)
Stromal corneal dystrophy 79 (1.5) 35 (1.5) 23 (1.9)
Aphakic corneal edema 102 (2.0) 30 (1.3) 14 (1.2)
Optical/refractive 67 (1.3) 36 (1.6) 14 (1.2)
Microbial/postmicrobial keratitis 76 (1.5) 32 (1.4) 13 (1.1)
Noninfectious ulcerative keratitis 177 (3.4) 38 (1.6) 10 (0.7)
Chemical injures 36 (0.7) 8 (0.3) 3 (0.2)
Other (leucoma by unknown cause;
silicone keratopathy; inborn opacities)
217 (4.2) 87 (3.7) 38 (3.1)
Previous keratoplasty 0.369
No 4,094 (86.1) 1,896 (86.2) 1,020 (87.3)
Yes 663 (13.9) 303 (13.8) 148 (12.7)
Unreported 453 130 55
Previous surgery (except keratoplasty) 0.120
No 3,251 (68.3) 1,610 (73.2) 884 (75.7)
Yes 284 (31.7) 589 (26.8) 284 (24.3)
Unreported 453 130 55
Other ocular diseases 0.345
No 3,700 (77.2) 1,734 (77.0) 939 (78.5)
Yes 1096 (22.8) 515 (23.0) 257 (21.5)
Unreported 414 81 27
Systemic diseases 0.455
No 3,657 (78.6) 1,723 (77.8) 933 (78.9)
Yes 997 (21.4) 491 (22.2) 249 (21.1)
Unreported 556 116 41
∗Proportion of the eligible patients; n.c.: data not collected; †comparison between interviewed and eligible.
In order to assess the magnitude and meaning of health
status changes we use the eﬀect size (ES) calculated by taking
the diﬀerences between means before treatment and after
treatment and dividing it by the SD of the same measure
before treatment. As suggested by Kazis et al. [28], small
magnitude of change is indicated by an eﬀect size of 0.2,
moderate by 0.5 and large by 0.8.
3. Results andDiscussion
3.1.Patients’Demography,Baseline,andAssessmentsOneYear
following Surgery . A total of 2,329 patients (44.7%) were
considered to be eligible over the total of 5,210 that under-
went corneal transplantation during the study period.
Among the eligible patients, 785 (33.7%) missed the
baseline interview (529 did not answer the phone call, 92
declinedtheconsent,89underwentsurgeryatanearlierdate,
56 had linguistic problems, and 19 did not answer for other
reasons). A further 321 patients (13.8%) missed the one-
year-after-surgery interview and were therefore excluded
from the analysis (185 did not answer the phone call, 92
refused the interview; 31 had been already regrafted because
of graft failure, and 13 had diﬃculty in carrying on the inter-
view).
Ultimately, 1,223 patients (52.5%) referring to 96 oph-
thalmic surgeons in 66 centers answered the two SF-12 and
the satisfaction questionnaire.
Sociodemographic and clinical characteristics of the en-
tire cohort, eligible and interviewed patients are reported in
Table 1.
A signiﬁcant diﬀerence between interviewed and eligible
patients (P = 0.026) was found only for the variable “reasons
for graft.”
Best corrected visual acuity (BCVA) before transplan-
tation is reported in Table 4. One year after surgery, 399
(32.6%) patients had BVCA of 8/10 or greater, 667 (54.6%)
were between 3/10 and 7/10, and 91 (12.8%) had a visual
acuity less than 2/10.
A total of 54 (4.4%) grafts failed and one or more adverse
reactions/complications (AE/C), for example, IOP elevation,
suture-related problems, and rejection episodes, occurred in
188 (15.4%) patients within the ﬁrst year of follow-up.
3.2. Overall Health Status Graded by Patients. The answers to
the ﬁrst item of SF-12 at baseline (in general, would you sayJournal of Ophthalmology 5
Table 2: Health in general at baseline (T0) and after one year (T1) in males.
T1
Excellent/very good N (%) Good N (%) Fair/poor N (%) Total N (%)
T0
Excellent/very good 142 (19.7) 81 (11.3) 7 (1.0) 230 (32.0)
Good 111 (15.4) 293 (40.8) 31 (4.3) 435 (60.5)
Fair/poor 6 (0.8) 29 (4.0) 19 (2.7) 54 (7.5)
Total 259 (35.9) 403 (56.1) 57 (8.0) 719 (100.0)
Table 3: Health in general at baseline (T0) and after one year (T1) in females.
T1
Excellent/very good N (%) Good N (%) Fair/poor N (%) Total N (%)
T0
Excellent/very good 46 (9.1) 54 (10.7) 1 (0.2) 101 (20.0)
Good 39 (7.8) 211 (41.9) 48 (9.5) 298 (59.2)
Fair/poor 6 (1.2) 47 (9.3) 52 (10.3) 105 (20.8)
Total 91 (18.1) 312 (61.9) 101 (20.0) 504 (100.0)
yourhealthisexcellent,verygood,good,fair,poor)showedthat
the large majority of males and females grade their health in
general as excellent/very good or good (Tables 2 and 3).
One year after surgery, males considered their health
statustobeimproved(20.2%),worse(16.6%),orunchanged
(63.2%),comparedtobaseline.Inthefemalesgroup,thecor-
responding ﬁgures were 18.3%, 20.4%, and 61.3%.
3.3. Physical (PCS-12) and Mental (MCS-12) Health Status at
BaselineandafterOneYear. Scoresgivenbymaleswerehigh-
erthanscoresgivenbyfemales,bothatbaselineandafterone
year.
Meaningful diﬀerences were observed within both SF-12
summary component scores across the distribution of dem-
ographic and clinical variables (Table 4).
Since the reliability of SF-12 summary scores is not as-
sured for small numbers, results in categories with less than
100 cases should be considered with caution (i.e., some age
groups, widow/divorced, no education, student, jobless, and
visual acuity higher than 5/10).
For the patient sample as a whole, the mean PCS-12
remained unchanged (ES = 0.09) but variations of MCS-12
suggest improvement of HRQOL with a small magnitude
of change (ES = 0.19). Considering males and females sep-
arately, transplantation did not inﬂuence physical health
in males (PCS-12 ES = −0.01) and had a negative eﬀect
in females (PCS-12 ES = −0.18). However, mental health
improved in both genders after one year (MCS-12 ES = 0.18
and 0.23, resp.).
Asfaraspatients’ ageisconcerned, PCS-12showed slight
changes while MCS-12 increased after transplantation in
several age intervals of both genders.
Physical health was not aﬀected by almost all demo-
graphic and socioeconomic variables or decreased only in
some cases (married people, people with low level of educa-
tion, and retired people) with negative ES values ranging
from 0.16 to 0.23. On the other hand, mental health substan-
tially increased, with positive MCS-12 ES values from 0.16 to
0.28.
Systemic diseases and AE/C reported in follow-up were
associated with a poorer PCS-12 after corneal transplanta-
tion (ES = −0.21 and −0.24, resp.) but all health and eye-
relatedvariablescorrelatedpositivelywithincreasedMCS-12
values at one year (ES ranging from 0.10 to 0.23).
3.4. Patient Satisfaction and SF-12 Comparison with the Ital-
ianValidationSurvey. Themajority ofpatientsweresatisﬁed
with the graft and would decide to undergo surgery again.
They considered their graft had been worthwhile (Table 5).
However, 24.0% of patients believed that the outcome did
not match their expectations, and 22.2% reported that they
had experienced more complications than expected.
No diﬀerences were found in the satisfaction with graft
outcome between genders (P = 0.5), while AR/C in follow-
up and a visual acuity of ≤2/10 after one year were found
to be signiﬁcantly associated with unhappiness with graft
outcome (P<0.001).
Distributionsofanswerstothesixthitemofthequestion-
naire (Overall, how much satisﬁed are you with your graft?)
showed 10.3% of patients to be unsatisﬁed and 2.9% to be
uncertain (Table 6). No signiﬁcant diﬀerences between sexes
were found (P = 0.3).
As assessed in the SF-12 validation study on more than
61,000 subjects [3, 27], females show poorer HRQOL than
males with mean (SD) values of PCS-12 and MCS-12 of 49.1
(10.1) and 48.9 (9.4) and 51.1 (8.7) and 51.5 (9.1), respec-
tively.
In the same study, about30,000 healthysubjectsreported
PCS-12 values of 53.7 (6.0) and MCS-12 of 52.8 (7.9). As
expected, diseased patients showed clear decreases of both
summary components, with PCS-12 scores ranging from
45.9 (11.0) to 37.2 (11.1) in patients with migraine and
past stoke and MCS-12 scores ranging from 46.0 (11.5)6 Journal of Ophthalmology
Table 4: PCS-12 and MCS-12 (mean and 95% CI) and eﬀect size (ES) by subgroups.
PCS-12 MCS-12
NT 0 T1 ES
∗ T0 T1 ES
∗
Total 1,223 50.8 (50.4–51.2) 50.2 (49.8–50.6) 0.09 48.4 (47.8–49.0) 50.4 (49.8–51.0) 0.19
Gender
Male 719 51.5 (51.0–51.9) 51.4 (50.9–51.9) −0.01 50.8 (50.1–51.4) 52.4 (51.7–53.1) 0.18
Female 504 49.9 (49.3–50.6) 48.5 (47.8–49.2) −0.18 45.0 (44.0–46.0) 47.6 (46.6–48.6) 0.23
Male, age groups (y)
18–24 88 52.8 (51.5–54.2) 52.5 (51.3–53.7) −0.06 49.8 (47.8–51.9) 51.0 (48.9–53.0) 0.12
25–34 178 51.9 (51.0–52.8) 52.7 (51.9–53.5) 0.13 50.5 (49.3–51.7) 53.1 (52.0–54.2) 0.33
35–44 155 51.5 (50.6–52.5) 51.5 (50.5–52.6) — 49.8 (48.2–51.3) 51.2 (49.7–52.6) 0.15
45–54 111 52.1 (50.8–53.3) 51.3 (50.0–52.6) −0.11 49.3 (47.3–51.2) 51.3 (49.4–53.1) 0.19
55–64 85 50.3 (49.1–51.6) 51.0 (49.7–52.1) 0.10 52.2 (50.1–54.2) 54.9 (53.3–56.6) 0.29
65–74 59 50.8 (49.6–52.1) 48.4 (46.7–50.0) −0.49 55.0 (53.2–56.8) 54.6 (52.2–57.0) −0.06
≥75 43 48.4 (46.1–50.7) 49.4 (47.0–51.8) 0.13 52.5 (49.4–55.7) 51.9 (48.1–55.6) −0.06
Female, age groups (y)
18–24 27 52.6 (50.1–55.1) 52.2 (49.9–54.5) −0.07 43.6 (39.1–48.2) 50.4 (46.1–54.6) 0.60
25–34 108 50.3 (48.8–51.8) 50.8(49.6–52.0) 0.06 42.1 (40.0–44.2) 45.7 (43.6–47.8) 0.33
35–44 91 51.2 (49.6–52.7) 49.9 (48.3–51.5) −0.17 44.9 (42.6–47.1) 48.6 (46.4–50.9) 0.35
45–54 101 50.5 (48.9–52.0) 49.4 (48.0–50.8) −0.14 45.1 (42.9–47.3) 48.0 (45.8–50.2) 0.26
55–64 72 49.8 (48.3–51.3) 47.4 (45.3–49.4) −0.38 47.6 (44.8–50.3) 48.2 (45.6–50.8) 0.05
65–74 70 48.4 (46.6–50.1) 45.7 (43.6–47.9) −0.36 48.0 (45.7–50.3) 49.4 (46.2–52.5) 0.14
≥75 35 45.7 (43.1–48.3) 41.6 (38.2–44.9) −0.52 43.8 (39.9–47.7) 43.3 (39.5–47.0) −0.05
Marital status
Married 676 51.1 (50.6–51.5) 50.0 (49.4–50.5) −0.16 48.8 (48.1–49.6) 50.6 (49.8–51.4) 0.17
Single 412 51.3 (50.6–51.9) 51.5 (50.9–52.1) 0.04 48.3 (47.3–49.3) 50.8 (49.9–51.7) 0.24
Widow/divorced 96 47.2 (45.6–48.8) 45.9 (43.9–47.8) −0.17 45.6 (43.0–48.1) 47.7 (45.2–50.4) 0.17
Education
High school 457 51.2 (50.6–51.8) 51.2 (50.6–51.8) — 48.1 (47.1– 49.0) 50.1 (49.2–51.0) 0.20
Secondary school 311 51.1 (50.3–51.9) 50.1 (49.4–50.9) −0.13 48.2 (47.1–49.4) 51.2 (50.0–52.3) 0.28
Primary school 227 49.0 (48.2–49.9) 47.5 (46.4–48.5) −0.23 49.0 (47.6–50.4) 50.7 (49.2–52.1) 0.16
Degree 143 52.7 (51.8–53.6) 52.4 (51.4–53.4) −0.05 49.0 (47.4–50.7) 50.6 (49.2–52.1) 0.16
None 22 46.8 (42.6–50.9) 44.9 (41.2–48.5) −0.19 47.7 (42.9–52.6) 43.1 (37.5–48.7) −0.39
Working status 0.21
Worker 632 51.7 (51.2–52.2) 51.5 (51.0–52.0) −0.04 49.2 (48.4–49.9) 51.2 (50.5–52.0) 0.07
Retired 222 49.2 (48.3–50.1) 47.6 (46.6–48.7) −0.23 50.8(49.5–52.1) 51.5 (50.0–53.0) 0.20
House keeper 181 48.9 (47.8–50.0) 47.8 (46.6–49.0) −0.15 44.9 (43.2–46.5) 47.2 (45.5–48.9) 0.26
Student 65 51.6 (50.1–53.0) 52.3 (51.0–53.6) 0.12 47.0 (44.6–49.4) 49.7 (47.6–51.8) 0.41
Unemployed 36 52.2 (50.5–53.9) 51.1 (49.5–52.7) −0.16 43.9 (41.1–46.7) 48.7 (46.3–51.0)
Systemic diseases
No 933 51.3 (50.9–51.7) 51.0 (50.6–51.5) −0.04 48.5(47.9– 49.2) 50.6 (50.0–51.3) 0.20
Yes 249 49.1 (48.1–50.0) 47.5 (46.4–48.5) −0.21 48.1 (46.8–49.5) 49.6 (48.1–51.0) 0.13
Unreported 41
Clinical indications
Ectasia/thinning 721 51.7 (51.2–52.1) 51.3 (50.8–51.7) −0.07 48.4 (47.6–49.1) 50.7 (50.0–51.4) 0.23
All other indications 502 49.5 (48.9–50.2) 48.7 (48.0–49.4) −0.12 48.4 (47.6–49.1) 50.1 (49.0–51.1) 0.14Journal of Ophthalmology 7
Table 4: Continued.
PCS-12 MCS-12
NT 0 T1 ES
∗ T0 T1 ES
∗
Previous keratoplasties
No 1,020 50.9 (50.5–51.3) 50.3 (49.8–50.7) −0.09 48.3 (47.7–49.0) 50.5 (49.8–51.1) 0.20
Yes 148 50.1 (48.9–51.3) 49.4 (48.1–50.6) −0.09 48.4 (46.5–50.2) 49.5 (47.6–51.5) 0.10
Unreported 55
Previous ocular surgery (other
than graft)
No 884 51.5 (51.0–51.9) 50.8 (50.4–51.3) −0.10 48.2 (47.5–48.9) 50.5 (49.8–51.1) 0.22
Yes 284 48.8 (47.9–49.6) 48.1 (47.0–49.1) −0.09 48.9 (47.5–50.2) 50.1 (48.7–51.5) 0.10
Unreported 55
Other ocular diseases
No 939 51.0 (50.6–51.5) 50.6 (50.1–51.0) −0.07 48.0 (47.4–48.7) 50.2 (49.6–51.0) 0.20
Yes 257 50.0 (49.1–50.9) 49.1 (48.2–50.1) −0.12 49.4 (48.1–50.7) 51.0 (49.7–52.3) 0.15
Unreported 27
Adverse
reactions/complications
(follow-up)
No 809 50.9 (50.4–51.4) 50.7 (50.3–51.2) −0.02 48.7 (48.0–49.4) 50.9 (50.2–51.6) 0.21
Yes 188 51.6 (50.6–52.5) 49.9 (48.8–51.0) −0.24 47.3 (45.8–48.7) 48.9 (47.3–50.6) 0.16
Unreported 226
BCVA§ (at baseline)
≤2/10 922 50.7 (50.3–51.2) 50.4 (49.6–50.5) −0.10 48.5 (47.9–49.2) 50.6 (49.9–51.3) 0.20
3/10-4/10 188 50.8 (49.9–51.7) 51.1 (50.2–52.0) 0.04 48.6 (47.1–50.1) 49.8 (48.2–51.3) 0.11
5/10-7/10 76 51.7 (50.1–53.4) 50.4 (48.8–52.0) −0.18 46.8 (44.0–49.6) 50.7 (48.4–52.9) 0.31
≥8/10 5 52.1 (43.3–60.9) 47.7 (37.5–57.9) −0.62 50.9 (34.4–67.3) 55.9 (48.1–63.7) 0.38
Unreported 32
∗Negative values of ES indicate poorer SF-12 scores compared to baseline; §best corrected visual acuity.
Table 5: Patients’ expectation and satisfaction.
Questions Yes n (%) No n (%) Uncertain n (%)
(1) Are you happy with your graft outcome? 1,016 (83.1) 144 (11.8) 63 (5.1)
(2) Does the outcome match your expectation? 864 (70.6) 293 (24.0) 66 (5.4)
(3) Would you make the same decision again? 1,100 (90.0) 65 (5.3) 57 (4.7)
(4) Was having the graft worthwhile? 1,170 (95.7) 27 (2.2) 26 (2.1)
(5) Have you had more complications than you expected? 271 (22.2) 948 (77.5) 4 (0.3)
Table 6: Overall patients’ satisfaction.
Males n (%) Females n (%) Total n (%)
Completely 411 (57.2) 268 (53.2) 679 (55.5)
Quite 217 (30.2) 166 (33.0) 383 (31.3)
None 68 (9.5) 58 (11.5) 126 (10.3)
Uncertain 23 (3.1) 12 (2.3) 35 (2.9)
Total 719 (100.0) 504 (100.0) 1.223 (100.0)
to 33.8 (10.8) in patients with prostatic hypertrophy and
central nervous system pathologies, respectively. In the
present study, patients waiting for corneal transplantation
showed PCS-12 of 50.8 (6.9) and MCS-12 of 48.4 (10.5) with
SF-12 values lower than those of healthy population in both
genders (Table 4).
4. Conclusions
This is the ﬁrst report on the use of the SF-12 Health Survey
in corneal transplantation and one of the few longitudinal
studies that have assessed changes in the HRQOL in patients
whohaveundergonecornealgrafting.Thestudyshowedthat
the graft improves patients’ HRQOL and inﬂuences mental
health more than physical health.
Consistently with almost all the surveys using the
HRQOL, females showed poorer quality of life scores than
males. Moreover, our study showed that physical health in
females was negatively aﬀected by corneal transplantation8 Journal of Ophthalmology
while grafts in males did not change the PCS-12 baseline
values.
Sincenodiﬀerenceingraftoutcomesisexpectedbetween
the genders and satisfaction with grafts was the same for
males and females, the inconsistency of PCS-12 results could
highlight diﬀerences in perceptions between the sexes with
respect to the impact of grafting on physical health. Actually,
there are no obvious reasons why young or middle-aged
patients—that generally maintain a normal life style, with
minor limitation, while waiting for surgery—should have
reduced their physical health after the graft.
Conversely,thesigniﬁcantimprovementofmentalhealth
in both sexes shows that although the graft primarily aims
to improve visual function, corneal transplantation largely
aﬀects psychological and emotional aspects of self-perceived
health.
This result parallels the recent ﬁnding by Kymes and
coworkers [5] who showed that keratoconus signiﬁcantly
impairs mentalhealthmorethanallotherscalesoftheVisual
Function Questionnaire.
The restoration of sight is the most important purpose
of corneal grafting. However, since successful corneal trans-
plantation can improve both health and lifestyle of patients,
their personal feelings should be considered as a central issue
in their overall assessment.
Abbreviations
(HRQOL): Health-related quality of life
(SF-12): 12-item short-form health survey
(PK): Penetrating keratoplasty
(ALK): Anterior lamellar keratoplasty
(PCS-12): Physical component summary
(MCS-12): Mental component summary
(ES): Eﬀect size.
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